VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
CMS Pharmaceutical's CMS-D001 Receives NMPA Approval for Ulcerative Colitis and Crohn's Disease Clinical Trials
CMS Pharmaceutical's CMS-D001 Receives NMPA Approval for Ulcerative Colitis and Crohn's Disease Clinical Trials
May 26, 2026 06:30 CST Updated 06:50
Share:
CMS
Professional Drug Developer